News >

Therapeutics Beyond JAK Inhibitors Needed in Polycythemia Vera and Myelofibrosis

Ellie Leick
Published: Wednesday, Nov 27, 2019

Raajit K. Rampal, MD, PhD, a hematologic oncologist at Memorial Sloan Kettering Cancer

Raajit K. Rampal, MD, PhD
While JAK inhibitors have become a staple in treatment for select patients with polycythemia vera (PV) and myelofibrosis, further clinical trial efforts are needed for when patients fail on or are intolerant of this class of agents, explained Raajit K. Rampal, MD, PhD.

“There are a number of really interesting trials ongoing right now,” said Rampal, a hematologic oncologist at Memorial Sloan Kettering Cancer. “The landscape will eventually tell us which one is the most promising agent.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication